Working… Menu

ABC294640 in Refractory / Relapsed Multiple Myeloma (ABC-103)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02757326
Recruitment Status : Terminated (Expiration of National Cancer Institute (NCI) funding of the study.)
First Posted : May 2, 2016
Last Update Posted : May 20, 2019
Apogee Biotechnology Corporation
Duke University
National Cancer Institute (NCI)
Information provided by (Responsible Party):
RedHill Biopharma Limited